These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors. Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794 [TBL] [Abstract][Full Text] [Related]
7. New nucleoside analogs for patients with hematological malignancies. Robak T Expert Opin Investig Drugs; 2011 Mar; 20(3):343-59. PubMed ID: 21320002 [TBL] [Abstract][Full Text] [Related]
8. Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. Robak P; Robak T Expert Opin Investig Drugs; 2017 Nov; 26(11):1249-1265. PubMed ID: 28942659 [TBL] [Abstract][Full Text] [Related]
9. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia. Robak P; Robak T Curr Med Chem; 2012; 19(31):5294-318. PubMed ID: 22830347 [TBL] [Abstract][Full Text] [Related]
10. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. Wang Y; Zhang LL; Champlin RE; Wang ML Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675 [TBL] [Abstract][Full Text] [Related]
11. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. Tan SL; Liao C; Lucas MC; Stevenson C; DeMartino JA Pharmacol Ther; 2013 May; 138(2):294-309. PubMed ID: 23396081 [TBL] [Abstract][Full Text] [Related]
12. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review. Kaur M; Singh M; Silakari O Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087 [TBL] [Abstract][Full Text] [Related]
13. Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases. Tang S; Yu Q; Ding C Expert Opin Investig Drugs; 2022 Mar; 31(3):291-303. PubMed ID: 35130124 [TBL] [Abstract][Full Text] [Related]
15. Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors. Musumeci F; Sanna M; Greco C; Giacchello I; Fallacara AL; Amato R; Schenone S Expert Opin Ther Pat; 2017 Dec; 27(12):1305-1318. PubMed ID: 28705083 [TBL] [Abstract][Full Text] [Related]
16. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies. Robak T; Robak P Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253 [TBL] [Abstract][Full Text] [Related]
17. The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies. Robak P; Witkowska M; Wolska-Washer A; Robak T Expert Opin Drug Discov; 2023; 18(10):1065-1076. PubMed ID: 37438969 [TBL] [Abstract][Full Text] [Related]
18. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. Bajpai M IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898 [TBL] [Abstract][Full Text] [Related]
19. Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. Ponader S; Burger JA J Clin Oncol; 2014 Jun; 32(17):1830-9. PubMed ID: 24778403 [TBL] [Abstract][Full Text] [Related]
20. Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies. Lucas F; Woyach JA Target Oncol; 2019 Apr; 14(2):125-138. PubMed ID: 30927175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]